Inhalation Drug Products — MDI and DPI CMC Under OGD Product-Specific Guidance and ICH Q4B

The FDA product-specific guidance for your MDI reference listed drug tells you the exact cascade impactor, the exact flow rate, the exact stage mass acceptance criteria, and the exact number of actuations to collect per sampling event. It is the most prescriptive CMC guidance FDA publishes for any drug product class.

Following it exactly is the hardest part of an MDI ANDA, not because the analytical science is ambiguous, but because cascade impaction is exquisitely sensitive to ambient temperature and relative humidity, stage coating variability, and HPLC method precision. An MDI ANDA that fails OGD’s in vitro BE criteria by a single stage’s mass distribution doesn’t get a deficiency letter, it gets a Complete Response Letter, because the in vitro cascade impaction data is the surrogate for bioequivalence.

NGI Cascade Impaction APSD — Stage Cutoffs, MMAD Calculation, and the Ambient Condition Sensitivity That Produces OGD Stage Mass BE Failures

The Next Generation Impactor at the standard 28.3 L/min flow rate used for MDI characterization separates an aerosol into seven size fractions plus a micro-orifice collector, each stage capturing particles above its own aerodynamic cutoff diameter, running from roughly 11.72 μm at Stage 1 down through 6.40, 4.40, 3.30, 2.08, and 1.36 μm at Stages 2 through 6, to 0.98 μm at Stage 7, with anything smaller reaching the MOC. Drug mass recovered from each stage by validated HPLC quantification after stage washing builds the cumulative mass distribution from which mass median aerodynamic diameter and geometric standard deviation are calculated, MMAD as the diameter at the 50th percentile of cumulative mass and GSD as the ratio of the 84th percentile diameter to that MMAD. What makes this method genuinely fragile is its sensitivity to ambient conditions rather than any ambiguity in the underlying physics: particles containing hygroscopic components, sodium chloride or lactose among them, absorb moisture and grow in size at relative humidity above roughly 60%, shifting deposition to earlier, larger-cutoff stages, while temperature affects HFA propellant evaporation rate directly, meaning testing conducted even a few degrees above the specified range can produce a materially different, and spuriously smaller, particle size result for a suspension MDI. ICH Q4B Annex 4A sets the testing envelope specifically to control this sensitivity, 20°C plus or minus 2°C and 50% RH plus or minus 10%, with the impactor itself needing at least an hour of temperature equilibration before testing begins, and OGD’s bioequivalence criterion for an MDI ANDA compares each individual NGI stage mass against the reference listed drug’s mean stage mass within a defined tolerance, commonly ±15%, meaning a single stage falling outside that band, even where every other stage passes cleanly, is sufficient on its own to fail the in vitro BE standard.

OGD Product-Specific Guidance Compliance — BE Criteria, Q1/Q2/Q3 Sameness, and the Preliminary Scientific Engagement Strategy for Non-Standard Formulation Approaches

OGD’s product-specific guidances function as the definitive roadmap for MDI and DPI ANDA development precisely because they specify, for each reference listed drug, the exact impactor type and flow rate, the sameness criteria the generic formulation has to satisfy relative to the RLD’s qualitative and quantitative composition, and the specific in vitro bioequivalence acceptance criteria the stage mass comparison has to meet. That level of prescription cuts both ways: it removes ambiguity about what OGD will accept, but it also means any formulation approach that departs from Q1/Q2 sameness, a different propellant blend or a different surfactant system than the RLD uses, shifts the burden onto the ANDA sponsor to demonstrate comparative in vitro aerosol performance data sufficient to support bioequivalence despite that formulation difference, and doing that development work without first confirming OGD’s position through a preliminary scientific engagement risks a substantial resource investment built on an assumption OGD may not share. The published product-specific guidance for salbutamol/albuterol sulfate MDI products, developed against the Ventolin HFA reference listed drug, is widely cited in the industry as the most heavily referenced and litigated MDI PSG in OGD’s published portfolio precisely because it establishes such a clear precedent for how NGI stage mass comparison is actually applied as a bioequivalence standard, and DPI product-specific guidances carry a parallel structure requiring cascade impaction testing at a higher flow rate, commonly 60 L/min, reflecting the moderate-to-strong inspiratory effort a dry powder inhaler depends on for aerosolization, generally supplemented by testing at both a lower and a higher flow rate to document how aerosol performance varies with patient inspiratory effort for device labeling purposes.

Delivered Dose Uniformity, DPI Carrier Lactose Engineering, and the Flow-Rate Dependency Testing That Completes the Inhalation CMC Package

Delivered dose uniformity testing under ICH Q4B Annex 3 requires sampling across the device’s entire labeled life, not a single time point, using a dosage unit sampling apparatus to collect individual actuations at the beginning of canister life, the middle, and the end, for a 120-actuation canister that means actuations 1 through 3, 59 through 61, and 118 through 120 respectively, with each of the nine collected samples required to fall within 20% of label claim individually and the mean of all nine within 10%. Suspension HFA-MDIs carry a specific, well-documented failure mode here: propellant absorbs moisture at high humidity, altering canister internal pressure and actuation dynamics in ways that can shift dose delivery, meaning a DDU program that only tests under standard conditions and never stresses the canister at elevated humidity risks missing a real in-use failure mode that only appears under accelerated storage stress. DPI aerosol performance carries its own distinct formulation science, since drug particles in the 1 to 5 μm range are carried on coarse lactose particles by van der Waals forces and rely on the patient’s own inspiratory effort to generate enough aerodynamic drag to separate from the carrier, and adding a fraction of fine lactose to the blend, commonly 5 to 20% of total lactose content, competes for carrier surface sites and displaces drug particles more readily, genuinely improving dispersibility in a way that has to be optimized by design of experiments rather than assumed from a single blend ratio. Because DPI performance depends so directly on patient effort, the OGD PSG for a DPI ANDA typically requires cascade impaction testing not just at the specified bioequivalence flow rate but across a documented range, commonly spanning roughly 30 to 90 L/min, precisely so the label can accurately describe how aerosol performance changes across the range of inspiratory efforts real patients will actually generate.

The XGene MDI and DPI CMC Architecture — Formulation Development, APSD Method, DDU Protocol, OGD PSG Compliance, and NDA/ANDA Documentation Structure

The XGene MDI and DPI CMC Architecture is a structured inhalation drug product CMC development framework for NDA 505(b)(2) and ANDA submissions built around treating cascade impaction as the exacting, ambient-condition-sensitive bioequivalence surrogate FDA actually treats it as.

1. MDI/DPI Formulation Development Strategy — Optimize propellant, surfactant, and carrier lactose systems against the reference product’s Q1/Q2/Q3 sameness requirements before committing to a formulation approach that departs from them. 2. Cascade Impaction APSD Method Development and Validation — Build the NGI method under ICH Q4B Annex 4A-compliant ambient conditions with documented temperature and humidity monitoring at every testing event, not just method-development runs. 3. Delivered Dose Uniformity Program — Test beginning, middle, and end of device life per ICH Q4B Annex 3, including accelerated humidity stress testing for suspension MDIs where moisture-driven dose variability is a known risk. 4. OGD Product-Specific Guidance Compliance Strategy — Map the specific PSG’s BE criteria and sameness requirements against the proposed formulation early, and use a preliminary scientific engagement before investing development resources in any non-standard approach. 5. NDA/ANDA Documentation Architecture — Assemble the APSD, DDU, and formulation development data into a 3.2.P.2 through P.5 package built specifically around the PSG’s prescriptive requirements rather than a generic inhalation CMC template.

The output is the inhalation CMC package built around the ambient-condition control and stage-by-stage bioequivalence standard OGD actually applies, rather than a cascade impaction dataset generated under conditions close enough to pass casual review but not close enough to survive OGD’s stage mass comparison.

FDA’s OGD Product-Specific Guidances for MDI and DPI drug products establish the in vitro bioequivalence testing requirements this article’s analysis is built around, specifying impactor type, flow rate, sameness criteria, and stage mass acceptance criteria for each reference listed drug. ICH Q4B Annex 3: Delivered Dose Uniformity and ICH Q4B Annex 4A: In-Vitro Assessment of Fine Particle Dose establish the internationally harmonized DDU and cascade impaction standards equivalent to USP <601>, which itself establishes the specific NGI stage cutoff diameters at 28.3 L/min. FDA’s Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations (2014) supplements the OGD PSG framework with general CDER bioequivalence principles, and 21 CFR 314.92(a)(1) establishes the legal basis for in vitro cascade impaction serving as bioequivalence evidence for orally inhaled drug products.

For your MDI or DPI NDA or ANDA CMC package, can you confirm today that your cascade impaction APSD characterization was conducted at ICH Q4B Annex 4A-compliant ambient conditions with documented temperature and humidity monitoring at every sampling event, and that your delivered dose uniformity testing covers beginning, middle, and end of canister or device life per ICH Q4B Annex 3 with each of the nine samples within 20% of label claim?